Botulinum Toxin Type A is a potent neurotoxin that is produced by a gram-positive bacteria clostridium botulinum. Its utilization in the treatment of various medical condition has expanded over the years in both medical and esthetic uses. It is being preferred by most physicians due to its efficacy and lack of side effects. It can be used as monotherapy or combined therapy. The aim of this review study was to show the role and mechanism of action of Botulinum toxin type A in the treatment and prevention of hypertrophic scars and keloids. The clear mechanisms underlying hypertrophic scars and keloids are still not clearly understood; however, the mechanism of action of Botulinum toxin type A has been shown to include action on wound tension, action on collagen, and action on fibroblasts. Different randomized controlled trials, double-blind, and placebo-controlled studies have been conducted to investigate its use in treatment and prevention of hypertrophic scars and keloids, and it still is one of the active areas of research in Dermatology and related fields. Method: In March 2018, we performed a literature search in PubMed for clinical studies, clinical trials, case reports, controlled trials, randomized controlled trials, and systemic reviews. The search terms we used were "BOTULINUM TOXIN" AND "HYPERTROPHIC SCARS" OR "KELOIDS" (from 1980). The search resulted in 1000 articles, out of these 35 articles met our inclusion exclusion criteria. Our inclusion criteria included relevant original articles relevant, critical systemic reviews, and crucial referenced articles, exclusion criteria included duplicates and articles not published in English language. We have reviewed these papers to show the role and mechanism of action of Botulinum toxin type A in the treatment and prevention of hypertrophic scars and keloids.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jocd.12828 | DOI Listing |
Eur Arch Otorhinolaryngol
December 2024
Department of Otorhinolaryngology and Head- Neck Surgery, All India Institute of Medical Sciences, New Delhi, India.
Purpose: Orocervical (OCF) or pharyngocutaneous fistula (PCF) are one of the disastrous complications of head and neck cancer surgery. Conventional standards of management are predominantly conservative. Though a majority of such patients respond to conservative management, it nevertheless causes significant delay in wound healing.
View Article and Find Full Text PDFA 55-year-old female attended the Outpatient Urology Department for local anaesthetic flexible cystoscopy and intradetrusor botulinum toxin A injection. Having been diagnosed with urodynamics-proven low-grade detrusor overactivity in 2017, she was well-established on six-monthly Botox® injections. As part of her ongoing treatment, 100 units of Allergan Botox diluted with saline in a 10 mL syringe were injected via 20 punctures.
View Article and Find Full Text PDFFront Neurol
December 2024
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Background/objective: Preventive medications are crucial in migraine prevention. In cases of refractory migraine headaches, multiple medications may be required. We seek to identify a comprehensive list of preventive migraine headache medications that can be used as two, three, and four drug combinations without drug-drug interactions.
View Article and Find Full Text PDFIndian J Plast Surg
December 2024
Department of Plastic and Reconstructive Surgery, Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia.
To evaluate the possibility of improving and preventing the formation of postoperative hypertrophic and keloid scars using botulinum toxin type A (BTA). Scientific articles published in English have been systematically screened in PubMed/MEDLINE database over the entire period. The following information about the studies was analyzed: first author surname; year of publication; number of patients; average age; scar location; dosage of the drug administered; follow-up duration; scar assessment methods; results, incidence of hypertrophic and keloid scars formation.
View Article and Find Full Text PDFAm J Gastroenterol
November 2024
Department of Surgery, The University of Auckland, Auckland, New Zealand.
Introduction: Gastroparesis is a debilitating gastroduodenal disorder for which gastric peroral endoscopic myotomy (GPOEM) has emerged as an efficacious treatment option. However, response to GPOEM varies between 50% and 80%, such that preoperative predictors of treatment success are needed to guide patient selection.
Methods: We performed a systematic review to identify predictors of clinical and functional response to GPOEM among adult patients with gastroparesis (PROSPERO: CRD42023457359).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!